Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,545
  • Shares Outstanding, K 27,470
  • Annual Sales, $ 21,250 K
  • Annual Income, $ -16,050 K
  • EBIT $ 2 M
  • EBITDA $ 2 M
  • 60-Month Beta 0.35
  • Price/Sales 7.55
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 227.80% ( -14.95%)
  • Historical Volatility 71.87%
  • IV Percentile 90%
  • IV Rank 55.21%
  • IV High 394.16% on 10/18/24
  • IV Low 22.77% on 06/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 17
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 201
  • Open Int (30-Day) 111

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.19
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.60 +30.22%
on 11/21/24
6.55 -8.52%
on 11/27/24
+1.35 (+29.09%)
since 11/20/24
3-Month
3.96 +51.26%
on 11/18/24
6.55 -8.52%
on 11/27/24
+0.75 (+14.31%)
since 09/20/24
52-Week
3.96 +51.26%
on 11/18/24
11.92 -49.75%
on 12/28/23
-4.39 (-42.29%)
since 12/20/23

Most Recent Stories

More News
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

FRX.TO : 8.57 (+1.30%)
FENC : 5.99 (+2.57%)
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

FRX.TO : 8.57 (+1.30%)
FENC : 5.99 (+2.57%)
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

FRX.TO : 8.57 (+1.30%)
FENC : 5.99 (+2.57%)
Insider Sale: Director at $FENC (FENC) Sells 6,409 Shares

CHRIS A RALLIS, a director at $FENC ($FENC), sold 6,409 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 10.9% of their shares....

FENC : 5.99 (+2.57%)
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

FRX.TO : 8.57 (+1.30%)
FENC : 5.99 (+2.57%)
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

FRX.TO : 8.57 (+1.30%)
FENC : 5.99 (+2.57%)
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

FRX.TO : 8.57 (+1.30%)
FENC : 5.99 (+2.57%)
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

FRX.TO : 8.57 (+1.30%)
FENC : 5.99 (+2.57%)
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of...

FRX.TO : 8.57 (+1.30%)
FENC : 5.99 (+2.57%)
Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that...

FENC : 5.99 (+2.57%)
FRX.TO : 8.57 (+1.30%)

Business Summary

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 6.35
2nd Resistance Point 6.18
1st Resistance Point 6.08
Last Price 5.99
1st Support Level 5.81
2nd Support Level 5.64
3rd Support Level 5.54

See More

52-Week High 11.92
Fibonacci 61.8% 8.88
Fibonacci 50% 7.94
Fibonacci 38.2% 7.00
Last Price 5.99
52-Week Low 3.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar